Ivarmacitinib at both 4 mg and 8 mg doses was found to be efficacious in treating alopecia areata in a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback